Il devient de plus en plus clair que pour traiter efficacement les tumeurs solides, nous devons également nous intéresser au microenvironnement tumoral. Physiologiquement, les zones intratumorales peuvent présenter une disponibilité anormale en nutriments, un pH altéré ou encore des niveaux d’oxygène bas (hypoxie). Il est connu que l’adaptation hypoxique engendre des cellules tumorales qui sont plus difficiles à traiter indépendamment de l’approche thérapeutique. De plus, l’adaptation hypoxique est nécessaire pour la progression tumorale puisque cette dernière favorise des processus tels que: la survie cellulaire, la motilité, l’angiogenèse, le métabolisme du glucose, l’immunomodulation ainsi que la résistance aux médicaments. Ces phénotypes passent par la régulation des ARN messager (ARNm) et des micro ARN (miARN). Pour ces raisons, des efforts importants ont été déployés pour comprendre l’adaptation hypoxique et les interventions thérapeutiques potentielles pouvant la contrer. À l’heure actuelle, il y a un manque de cohérence et de variété dans les protocoles de traitement hypoxique in vitro qui ne tient pas compte des aspects importants de l’hypoxie in vivo, comme la réduction de la disponibilité en éléments nutritifs, la durée de l’exposition hypoxique ainsi que le degré d’hypoxie. Pour mieux simuler le microenvironnement hypoxique in vivo, nous avons développé de nouveaux protocoles hypoxiques in vitro qui visent à simuler ces aspects. Tout d’abord, en utilisant une lignée cellulaire B16-HIF1a-eGFP, nous avons optimisé le stress métabolique à court terme en conjonction avec l’hypoxie pour augmenter la stabilisation de l’HIF1a. Pour déterminer comment le programme HIF1 adapte les cellules à ces différentes conditions, nous avons analysé les données de séquencage d’ARN qui démontrent que le stress métabolique induit un programme transcriptionnel HIF1 plus robuste et diversifié dans les cellules hypoxiques, et que ce dernier est représentatif du stress hypoxique in vivo. Nous avons également identifié de nouveaux miARN induits par l’hypoxie et démontré que notre protocole d’incubation régule davantage les miRNA associés au pronostic négatif du patient. Nous avons aussi étudié l’adaptation hypoxique à long terme et extrême in vitro. Nous avons observé que l’incubation hypoxique à long terme induit une transition épithéliale à mésenchymateuse (TME), indépendante de l’expression différentielle des facteurs de transcription du TME canonique. Ce changement se produit à des niveaux spécifiques d’oxygène, et nécessite une pré-incubation à des niveaux hypoxiques plus faible. Avec ce protocole, nous avons découvert une nouvelle isoforme de WT1 (tWT1), un moteur potentiel du TME. tWT1 commence la transcription dans l’intron 5 du gène WT1, une région avec plusieurs séquences d’ADN contenant des éléments de réponse à l’hypoxie. La protéine tWT1 a une fonctionnalité limitée : elle est localisée au niveau du noyau, et conserve la liaison de l’ADN aux régions précédemment connues. Nous avons aussi identifié l’expression de tWT1 dans les échantillons de patients atteints de leucémie ainsi qu’une isoforme tWT1 potentiellement plus fonctionnelle grâce à des analyses par kmer. Pour cibler ces phénotypes identifiés dans nos expériences d’adaptation hypoxiques, nous avons développé une nouvelle catégorie d’ARN intérférent (ARNi) thérapeutique : le microARN synthétique (synmiR). Les synmiR sont des molécules de RNAi avec des multiples cibles. En utilisant des expériences in vivo, nous avons établi de nouveaux principes de RNAi qui élargissent considérablement l’espace de conception pour les synmiR. Nous avons mis au point deux algorithmes de conception de synmiR distincts et avons testé leur efficacité dans le contrôle de l’activité transcriptionnelle du génome du VIH in vivo. En conclusion, nous avons montré que l’inclusion de facteurs physiologiques supplémentaires associés à l’hypoxie in vitro entraîne un engagement plus robuste de l’adaptation de l’hypoxie. À ce jour, aucun de nos protocoles d’hypoxie n’a été reproduit dans la littérature. Nous contribuons aux connaissances dans le domaine en décrivant les nouveaux ARNm/miARN induits par l’hypoxie, ainsi que la méthode d’induction fiable de l’EMT par l’hypoxie seulement. Nous faisons également état de l’existence de nouveaux isoformes de WT1 et de leurs liens avec le cancer et l’hypoxie. La connaissance de ces isoformes est importante pour l’avenir de la recherche sur WT1, car elle pourrait faire la lumière sur des résultats auparavant inexplicables. Notre travail dans les synmiR ouvre une nouvelle voie d’investigation pour le traitement de certaines maladies, et fournit un mécanisme d’action testable pour les miRNA endogènes. Une fois suffisamment développés, les synmiR offrent une occasion thérapeutique unique d’exploiter leur multi-ciblage pour avoir un impact spectaculaire sur une seule voie, ou affecter plusieurs voies par le ciblage simultané de gènes clés. / It is becoming increasingly clear that in order to effectively treat solid tumours, we must also address the tumour microenvironment. Physiologically, intratumoral areas may have abnormal nutrient availability, pH, or lower oxygen levels (hypoxia). It is known that hypoxic adaptation results in tumour cells which are harder to treat regardless of therapeutic approach, and hypoxic adaptation is necessary for disease progression due to the induction of tumour promoting phenotypes such as, but not limited to: cell survival, motility, angiogenesis, glucose metabolism, immunomodulation, and drug resistance. This is accomplished through the regulation of both mRNAs and miRNAs. For these reasons, significant effort has been applied to understanding hypoxic adaptation and potential therapeutic interventions. Currently, there is a lack of consistency and protocol variety in in vitro hypoxic treatments that leaves out important aspects of in vivo hypoxia, such as reduced nutrient availability, length of hypoxic exposure, and degree of hypoxia. To better simulate the in vivo hypoxic microenvironment, we have developed new in vitro hypoxic protocols which aim to simulate these aspects. First, using a B16-HIF1α-eGFP hypoxia reporter cell line, we optimized short-term metabolic stress in conjunction with hypoxia to enhance HIF1α stabilization. To ascertain how the HIF1 program adapts the cells to these different conditions, deep transcriptome profiling were performed and demonstrated metabolic stress induces a more robust and diversified HIF1 transcriptional program in cells under hypoxia, which was more representative of in vivo hypoxic stress. We identified novel hypoxia-induced miRNAs as well, and demonstrated our incubation protocol regulated more miRNAs associated with negative patient prognosis. We also investigated long-term and extreme hypoxic adaptation in vitro. Long term hypoxic incubation induced a epithelial to mesenchymal transition (EMT), independent of canonical EMT factor differential expression. This switch occurred at specific oxygen levels, and required pre-incubation at milder hypoxic levels, highlighting the relevance of simulating in vivo hypoxia development in vitro. Through this protocol, we discovered a novel isoform of WT1 (tWT1), a potential driver of our EMT. tWT1 begins transcription within intron 5 of the WT1 gene, a region with several Hypoxia Response Elements DNA sequences. tWT1 retains limited functionality: it is able to localize to the nucleus, and retains DNA binding to previously known gene promoter regions. We also identified the expression of tWT1 in leukemic patient samples as well as a potentially more functional tWT1 isoform through kmer-based analyses. To target these multiple phenotypes identified in our hypoxia adaptation experiments, we worked towards developing a new category of RNA-interference (RNAi) therapeutic, the synthetic microRNA (synmiR). SynmiRs are single-sequence, multi-targeted RNAi molecules. Using in vivo knock-down experiments, we established new RNAi principles which dramatically expand the design space for synmiRs. We developed two philosophically distinct synmiR design algorithms, and validated their efficacy in controlling HIV genome transcriptional activity in vivo. In conclusion, we have shown the inclusion of additional physiological factors associated with hypoxia in vitro results in a more robust engagement of hypoxia adaptation. To date, neither of our hypoxia protocols have been replicated in the literature. We contribute to the literature by describing novel hypoxia induced mRNAs/miRNAs, as well as methods for reliably inducing EMT through hypoxia alone. We also discovered the existence of novel WT1 isoforms and their links to cancer and hypoxia. Knowledge of these isoforms is important for WT1 research moving forward, as it may shed light on previously unexplainable results. Our work in synmiRs opens a new therapeutic avenue for multiple disease states, and provides a testable mechanism of action for endogenous miRNAs. Once sufficiently developed, synmiRs offer a unique therapeutic opportunity to harness their multi-targeting to dramatically impact a single pathway, or affect multiple pathways through simultaneous targeting of key genes.

No description available.

Orientador: Ana Elizabete Silva / Banca: Maria Inês Moura Pardini / Banca: Fátima Pereira de Souza / Resumo: O câncer gástrico é a segunda causa de morte por câncer no mundo e o quinto tipo com maior prevalência no Brasil, sendo previstos 21.800 casos novos em 2008. Esta neoplasia apresenta etiologia bastante complexa, envolvendo fatores genéticos e ambientais. Os fatores etiológicos de maiores destaques incluem a infecção pela bactéria Helicobacter pylori, a ingestão de determinados alimentos, como defumados, enlatados e com elevada quantidade de sal, além do estilo de vida dos indivíduos, associado ao consumo de cigarro e álcool. Uma lesão pré-cancerosa importante no desenvolvimento da neoplasia gástrica é a metaplasia intestinal, podendo aumentar o seu risco em até 10 vezes. Atualmente é reconhecida a participação de alterações epigenéticas como metilação aberrante do DNA, que atua de forma igualmente relevante e complementar no processo de desenvolvimento e progressão do câncer. Vários genes com papel importante no controle do ciclo celular, reparo do DNA, apoptose, angiogênese e adesão celular podem apresentar expressão alterada devido metilação aberrante de sua região promotora, assim a investigação do padrão de metilação de genes envolvidos com o processo neoplásico pode ser uma estratégia interessante para a indicação de marcadores moleculares que possam auxiliar no diagnóstico precoce do câncer. Desta forma, no presente trabalho foi investigado o padrão de metilação dos genes WT1 e RARß em metaplasia intestinal (35 amostras) e suas respectivas mucosas gástricas normais, em comparação com o câncer gástrico (8 amostras) também com suas respectivas mucosas normais, através da técnica MS-PCR (Methylation Specific PCR). Devido à participação da infecção pela H. pylori na carcinogênese gástrica, foi investigada molecularmente a presença dessa bactéria nas amostras...(Resumo completo, clicar acesso eletrônico abaixo) / Abstract: Worldwide, the gastric cancer is the second cause of death by cancer. In Brazil, it is the fifth type with more abundant, foreseen 21.800 new cases in 2008. This neoplasia presents very complex etiology involving genetic and environmental factors. The main etiologic factors include: infection by H. pylori, intake of specific foods such as curing food, canned food, and high consumption of salt wealthy food, besides people life style associated to alcohol and cigarette consumptions. An important previous-cankered lesion in development of gastric neoplasia is the intestinal metaplasia, what can increase your risk in ten times. At this moment, it is recognized the participation of epigenetic alterations like ADN aberrant methylation, which actuate in a same way considerable and complementary in development process and cancer evolution. Many genes with important role in control of cellular cycle, ADN repair, apoptosis, angiogenesis and cellular adhesion can present changed expression due aberrant metthylation of your promoter region. In this manner, the investigation of metithyation pattern of genes involved with the neoplasic process can be an interesting strategy for the indication of molecular markers that can help in cancer precocious diagnosis. Thus, in this present study were investigated the metthylation pattern of RARß and WT1genes (35 samples) and their respective normal mucous gastrics by technic MSPCR (Methylation Specific PCR). Due to participation of infection by H. pylori in gastric carcinogenesis, it was too molecular investigated the presence of this bacterium in the studied samples and the possible association with the metthylation pattern presented by both genes. The results showed high pattern of methylation in both valued lesions, that is, 97% and 100%, respectively of methylated samples in metaplasia group ...(Complete abstract click electronic access below) / Mestre

Largely as a consequence of the ongoing obesity epidemic, research into adipose tissue biology has increased substantially in recent years. Worldwide, the number of people classed as overweight or obese is growing, and this represents a major public health concern. Adipose tissue is broadly divided into two types; white and brown. Whilst white adipose tissue (WAT) functions to store and mobilise triglycerides, brown adipose tissue burns chemical energy to generate heat. WAT is further divided into visceral “bad” fat and subcutaneous “good” fat depots, and it is an increase in the former that is linked to obesity-associated diseases. As well as adipocytes, several other cell types including haematopoietic and endothelial are found within adipose tissue, and comprise the stromal vascular fraction (SVF). Adipocyte precursor cells (APCs) also reside within the SVF and are essential for the maintenance and expansion of adipose tissue. The protein encoded by the Wilms’ tumour 1 (Wt1) gene is predominantly known to function as a transcription factor, but also has a role in post-transcriptional processing. Deletion of Wt1 in adult mice results in a considerable loss of fat tissue. Moreover, recent work has revealed that a proportion of the APCs from all visceral WAT depots express Wt1, therefore revealing heterogeneity within the APC population. Additionally, visceral WAT depots are encapsulated by a WT1 expressing mesothelial layer, which has its origins in the lateral plate mesoderm (LPM), and can give rise to mature adipocytes. Lineage tracing has demonstrated that a significant proportion of the mature adipocytes in all adult visceral WAT depots (but not subcutaneous) are derived from cells that express Wt1 in late gestation. These findings uncovered key ontogenetic differences between visceral and subcutaneous WAT and led us to ask whether Wt1 functions in visceral adipose tissue biology. Preliminary work has shown that adipocytes derived from Wt1 expressing (Wt1+) precursor cells have fewer, larger lipid droplets than those derived from non-Wt1 expressing (Wt1-) precursors. In this thesis, this heterogeneity is explored further using a Wt1GFP/+ knock-in mouse. When Wt1+ and Wt1- APCs are cultured separately, the Wt1+ population differentiate into adipocytes more readily. Moreover, the Wt1+ APCs are more proliferative than the Wt1-. Preliminary results also suggest that the Wt1+ APCs may secrete a factor(s) that causes the Wt1- APCs to exhibit improved adipogenic differentiation, a result that is supported by data from comparative transcriptomic analysis. Finally, the percentage of APCs decreases when mice are fed a high fat diet. Interestingly, this decrease is more pronounced for the Wt1+ population. Therefore, it appears that as well as exhibiting differing behaviours in vitro, the Wt1+ and Wt1- populations respond differently to physiologically relevant conditions in vivo. Whilst the LPM is a major source of visceral WAT, the origin of subcutaneous WAT is currently unknown. Here, the Prx1-Cre and Prx1-CreERT2 mouse lines are used to investigate this. It is shown that the majority of subcutaneous WAT adipocytes and APCs are labelled by Prx1-Cre, however this is not the case for most of the visceral WAT depots. The exception to this is the pericardial (heart fat) depot, in which approximately 70% of the adipocytes and 40% of the APCs are labelled. Moreover, a proportion of the Prx1-Cre labelled pericardial APCs also express Wt1, therefore suggesting additional heterogeneity. Preliminary results show that this heterogeneity may have functional consequences, at least in vitro. Additionally, lineage tracing studies suggest that the somatic LPM may be one source of subcutaneous WAT and pericardial visceral WAT Finally, it is shown that the conditional deletion of Wt1 in the Prx1-Cre lineage results in abnormal diaphragm development. Congenital diaphragmatic hernia (CDH) is severe birth defect, the etiology of which is not well understood. Here, a new model of CDH has been developed, and the cellular and molecular mechanisms responsible for the defect in this model are investigated.

Made available in DSpace on 2014-06-11T19:26:03Z (GMT). No. of bitstreams: 0 Previous issue date: 2008-02-28Bitstream added on 2014-06-13T18:29:22Z : No. of bitstreams: 1 silva_hm_me_sjrp.pdf: 508031 bytes, checksum: 56b635113c96c5bc5c2ffa3a4cb5324a (MD5) / Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) / Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) / O câncer gástrico é a segunda causa de morte por câncer no mundo e o quinto tipo com maior prevalência no Brasil, sendo previstos 21.800 casos novos em 2008. Esta neoplasia apresenta etiologia bastante complexa, envolvendo fatores genéticos e ambientais. Os fatores etiológicos de maiores destaques incluem a infecção pela bactéria Helicobacter pylori, a ingestão de determinados alimentos, como defumados, enlatados e com elevada quantidade de sal, além do estilo de vida dos indivíduos, associado ao consumo de cigarro e álcool. Uma lesão pré-cancerosa importante no desenvolvimento da neoplasia gástrica é a metaplasia intestinal, podendo aumentar o seu risco em até 10 vezes. Atualmente é reconhecida a participação de alterações epigenéticas como metilação aberrante do DNA, que atua de forma igualmente relevante e complementar no processo de desenvolvimento e progressão do câncer. Vários genes com papel importante no controle do ciclo celular, reparo do DNA, apoptose, angiogênese e adesão celular podem apresentar expressão alterada devido metilação aberrante de sua região promotora, assim a investigação do padrão de metilação de genes envolvidos com o processo neoplásico pode ser uma estratégia interessante para a indicação de marcadores moleculares que possam auxiliar no diagnóstico precoce do câncer. Desta forma, no presente trabalho foi investigado o padrão de metilação dos genes WT1 e RARß em metaplasia intestinal (35 amostras) e suas respectivas mucosas gástricas normais, em comparação com o câncer gástrico (8 amostras) também com suas respectivas mucosas normais, através da técnica MS-PCR (Methylation Specific PCR). Devido à participação da infecção pela H. pylori na carcinogênese gástrica, foi investigada molecularmente a presença dessa bactéria nas amostras... / Worldwide, the gastric cancer is the second cause of death by cancer. In Brazil, it is the fifth type with more abundant, foreseen 21.800 new cases in 2008. This neoplasia presents very complex etiology involving genetic and environmental factors. The main etiologic factors include: infection by H. pylori, intake of specific foods such as curing food, canned food, and high consumption of salt wealthy food, besides people life style associated to alcohol and cigarette consumptions. An important previous-cankered lesion in development of gastric neoplasia is the intestinal metaplasia, what can increase your risk in ten times. At this moment, it is recognized the participation of epigenetic alterations like ADN aberrant methylation, which actuate in a same way considerable and complementary in development process and cancer evolution. Many genes with important role in control of cellular cycle, ADN repair, apoptosis, angiogenesis and cellular adhesion can present changed expression due aberrant metthylation of your promoter region. In this manner, the investigation of metithyation pattern of genes involved with the neoplasic process can be an interesting strategy for the indication of molecular markers that can help in cancer precocious diagnosis. Thus, in this present study were investigated the metthylation pattern of RARß and WT1genes (35 samples) and their respective normal mucous gastrics by technic MSPCR (Methylation Specific PCR). Due to participation of infection by H. pylori in gastric carcinogenesis, it was too molecular investigated the presence of this bacterium in the studied samples and the possible association with the metthylation pattern presented by both genes. The results showed high pattern of methylation in both valued lesions, that is, 97% and 100%, respectively of methylated samples in metaplasia group ...(Complete abstract click electronic access below)

Nous avons découvert que TRF2 est aussi sur-exprimée au niveau des cellules endothéliales de nombreux types de cancers humains alors qu’elle n’est pas détectable dans les vaisseaux des tissus sains adjacents. Des cellules endothéliales extraites de tumeurs ex-vivo manifestent une expression supérieure de TRF2, une migration et une prolifération accrues et une aptitude à former des tubules élevée, comparées aux endotheliums isolées de tissus sains. La sur-expression de cette protéine in vitro dans des cellules endothéliales primaires et ex-vivo entraine l’augmentation de la prolifération, de la migration et de la capacité de ces dernières à former des tubules. La diminution de l’expression de TRF2 conduit à l’effet inverse. Par ailleurs, la modulation de l’expression de TRF2 n’affecte pas la proportion de cellules apoptotiques. De même, les variations des niveaux d’expression de TRF2 n’induisent aucune réponse aux dommages à l’ADN et les modifications des facultés angiogéniques sont indépendantes d’ATM. Les effets angiogéniques de TRF2 semblent donc distincts des fonctions télomériques. Etant donné que le facteur de transcription WT1 (Wilms’ tumour suppressor 1) est fortement exprimé dans les vaisseaux de tumeurs humaines et régule les propriétés angiogéniques des cellules endothéliales, nous nous sommes penché sur la régulation potentielle de TRF2 par WT1. WT1 se lie en effet sur le promoteur de TRF2 pour activer sa transcription. Enfin, nous avons démontré que l’activité angiogénique de TRF2 réside en partie dans sa capacité à se fixer sur le promoteur du gène codant pour le récepteur angiogénique à activité tyrosine kinase PDGFRβ et à activer sa transcription. / We discovered that TRF2 is expressed in endothelial cells of many human cancer types but not in the vessels of healthy adjacent tissues. Endothelial cells derived from tumours ex vivo exhibited a significantly increased TRF2 expression, and a higher migration, proliferation and tube formation potential as endothelium obtained from healthy tissues. In vitro TRF2 over-expression in primary or ex vivo endothelial cells resulted in an increased proliferation, migration and tube formation, while silencing of TRF2 led to the opposite results. No changes in apoptosis could be observed. Interestingly, modulation of TRF2 in endothelium does not induce DNA damage responses and the observed changes in the angiogenic behaviour are ATM –independent. The angiogenic effects of TRF2 seem therefore to be uncoupled from its telomeric function. Since the transcription factor WT1 (Wilms’ tumour suppressor 1) is highly expressed in human tumour vessels and mediates angiogenic properties of endothelial cells, we investigated whether TRF2 expression could be regulated by WT1. Indeed, WT1 binds the TRF2 promoter and activates its transcription. Finally, we demonstrated that TRF2 promotes angiogenesis by binding to the promoter of the gene encoding for the angiogenic tyrosine kinase receptor PDGFRβ and activating its transcription.

No description available.